One approval, one molecule
Obstructive sleep apnea and excess weight are closely linked, and people considering a GLP-1 medication often have both. The regulatory position is simpler than the conversation around it. One product, Zepbound®, which contains tirzepatide, is FDA-approved to treat moderate to severe obstructive sleep apnea in adults with obesity. Semaglutide has no such approval. Compounded versions of either molecule are approved for nothing. This guide reports what the Zepbound® label and the published trial found, what the label does not claim, and what a provider weighs when sleep apnea is part of the picture.
This is general information and not medical advice. The approval and the trials belong to Zepbound®, the branded product. Personalized Compounded tirzepatide, which Bodi Envi’s programs may include, is not FDA-approved, was not studied in these trials and is not equivalent to Zepbound®. Sleep apnea is a diagnosed condition with its own treatments, and your licensed provider, together with whoever treats your sleep apnea, is the person to ask.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the Zepbound® label says
The Zepbound® prescribing information lists two indications, both in combination with a reduced calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with a weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. For the sleep apnea indication, the label gives a maintenance dose of 10 mg or 15 mg once weekly, reached through the same escalation from 2.5 mg that it describes for weight management, with 15 mg the maximum.
The label’s mechanism section does not explain the sleep apnea effect separately. It describes tirzepatide as activating the GIP and GLP-1 receptors, both found in areas of the brain involved in appetite regulation, and reports that it lowers body weight with greater fat mass loss than lean mass loss. The clinical studies section reports the trial results, which are the evidence for the indication.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the trials found in brand name medication
The label’s obstructive sleep apnea studies section describes two randomized, double-blind, placebo-controlled trials of 52 weeks, run under one master protocol and enrolling 469 adults in total, all with moderate to severe obstructive sleep apnea, defined by an apnea-hypopnea index of 15 or more events per hour, and obesity, defined by a body mass index of 30 or more. Patients with type 2 diabetes were excluded. Tirzepatide was escalated over up to 20 weeks to a maximum tolerated dose of 10 mg or 15 mg. Study 5 enrolled 234 patients who were unable or unwilling to use positive airway pressure therapy; Study 6 enrolled 235 patients who were using it. In both, the mean baseline apnea-hypopnea index was around 50 events per hour, roughly two thirds of patients had severe disease, and the mean body mass index was about 39.
The primary endpoint was the change in the apnea-hypopnea index at week 52. Per the label, in Study 5 the index fell by 25.3 events per hour with tirzepatide against 5.3 with placebo, a difference of 20 events per hour; in Study 6 it fell by 29.3 against 5.5, a difference of 23.8. As a percentage of baseline, the reductions were 50.7 and 58.7 percent with tirzepatide against 3 and 2.5 percent with placebo. The proportion of patients whose index fell by at least half was 61.2 percent against 19 percent in Study 5 and 72.4 percent against 23.3 percent in Study 6. The proportion reaching remission or mild non-symptomatic disease, defined as an index below 5, or between 5 and 14 with a low sleepiness score, was 42.2 percent against 15.9 percent and 50.2 percent against 14.3 percent. Body weight fell by 17.7 and 19.6 percent with tirzepatide against 1.6 and 2.3 percent with placebo, and the label reports greater reductions in hypoxic burden, systolic blood pressure and high-sensitivity C-reactive protein.
SURMOUNT-OSA, the published report of the same two trials by Malhotra and colleagues in the New England Journal of Medicine in 2024, gives the same primary results in its abstract on PubMed, with confidence intervals, and reports that the most frequently reported adverse events with tirzepatide were gastrointestinal and mostly mild to moderate. Its authors’ summary is that among persons with moderate to severe obstructive sleep apnea and obesity, tirzepatide reduced the apnea-hypopnea index, body weight, hypoxic burden, hsCRP concentration and systolic blood pressure and improved sleep-related patient-reported outcomes. Brand name studies cannot be applied to personalized compounded versions of the medications. No studies have been completed on personalized compounded medications and they cannot be compared.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the label does not claim
Two limits are stated in the label itself. In Study 6, patients on positive airway pressure therapy were instructed to suspend it for seven days before the primary endpoint was assessed, and the label states that the studies did not evaluate the timing or appropriateness of stopping PAP in patients who were previously compliant with it. The trials measured what happened to the index when the machine was paused; they did not test replacing it. And the label reports that a reduction in the index was observed irrespective of age, sex, ethnicity, baseline body mass index or baseline severity, which is a statement about the trial population as a whole, not a prediction for any one person.
The figures are also means. Around 40 to 50 percent of treated patients did not reach remission or mild disease in either study, and around 30 to 40 percent did not halve their index. The trials studied Zepbound® at its highest doses for a year in people with obesity and confirmed moderate to severe disease, alongside diet and activity, and their results describe that setting.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Semaglutide and sleep apnea
The Wegovy® label lists its indications as reducing cardiovascular risk in adults with established cardiovascular disease and obesity or overweight, weight reduction and maintenance, and a liver condition. Obstructive sleep apnea is not among them. This guide has no FDA-approved label and no peer reviewed trial of semaglutide in sleep apnea to cite, and so it says nothing about what semaglutide does or does not do for the condition. The absence of an indication is not evidence either way; it is the absence of an approved claim.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What compounded products carry
Nothing. The FDA’s human drug compounding page states that compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed. An indication is a property of an approved product, granted on the evidence submitted for that product, and personalized compounded tirzepatide has no indication for sleep apnea, for weight management or for anything else. Bodi Envi states that personalized compounded tirzepatide is not FDA-approved and is not equivalent to FDA-approved products.
A provider may of course know the Zepbound® evidence and take it into account when evaluating a patient with sleep apnea. That is clinical judgment applied to the published trials, and it is the provider’s to exercise; it is not a claim that a compounded product does what Zepbound® was shown to do.
What this means when you talk to a provider
If you have sleep apnea, or think you might, it belongs in your assessment. A provider will want to know whether it has been diagnosed and how severe it is, whether you use positive airway pressure therapy and how consistently, and who treats it, because the label’s own statement about PAP means that decision stays with a treating clinician and not with a weight management program. Both labels also warn about pulmonary aspiration during general anesthesia or deep sedation, which is relevant to anyone whose sleep apnea care involves procedures, and about the gastrointestinal effects that concentrate during escalation.
Bodi Envi is a LegitScript-certified U.S. telehealth platform that connects eligible adults with licensed healthcare providers for personalized medical weight-management care; it is not a medical practice, pharmacy or medication manufacturer, and it does not treat sleep apnea. Clinical services for applicable programs are provided by Wasef Health, PC, and a licensed provider determines whether treatment is appropriate for each individual patient. This guide is general information and not medical advice; the label and trial cited describe Zepbound®, not personalized compounded tirzepatide; and your provider and your sleep clinician are the people to ask.